Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
PHASQ PhaseBio Pharmaceuticals
0.0150.0000.00%
Close
02/07 16:00 ET
High
0.015
Open
0.015
Turnover
20.16
Low
0.015
Pre Close
0.015
Volume
1.36K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Bankrupt PhaseBio Pharma Finds Buyers for Secondary Assets After Auction -- Market Talk
1601 ET - Publicly traded PhaseBio Pharmaceuticals, which has already reached a deal to sell its key drug program during its bankruptcy, says it has also found proposed buyers for its secondary assets
SFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets From PhaseBio Pharmaceuticals
SFJ Pharmaceuticals ("SFJ" or the "company") today announced the closing of the sale and transfer of assets related to Bentracimab from PhaseBio Pharmaceuticals, Inc. ("PhaseBio") to SFJ. The sale and transfer was
Delisting of Securities of PhaseBio Pharmaceuticals, Inc.; Zovio Inc.; Fast Radius, Inc.; and Kismet Acquisition Three Corp. From The Nasdaq Stock Market
NEW YORK, Dec. 20, 2022 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of PhaseBio Pharmaceuticals, Inc. PhaseBio Pharmaceuticals, Inc.'s common stock was suspended on
PhaseBio Pharmaceuticals (NASDAQ:PHAS) Trading Up 7%
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS – Get Rating) shares were up 7% during trading on Wednesday . The stock traded as high as $0.11 and last traded at $0.10. Approximately 455,938 shares chan
Bankrupt PhaseBio Identifies Chiesi as Lead Bidder for Bentracimab Assets
By Becky Yerak Chiesi Farmaceutici SpA has been named as the lead bidder for the key assets of PhaseBio Pharmaceuticals Inc., a publicly traded drug developer that is in chapter 11 bankruptcy. Phase
News On PhaseBio Pharmaceuticals Inc. (PHAS) Now Under PHASQ
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Monopar Therapeutics (NASDAQ:MNPR) shares increased by 53.0% to $4.09 during Wednesday's pre-market session. The company's market cap stands at $52.0 million.Arcturus Therapeutics (NASDAQ:ARCT
Head to Head Analysis: PhaseBio Pharmaceuticals (NASDAQ:PHAS) Vs. Alpine Immune Sciences (NASDAQ:ALPN)
PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) and Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the
Head-To-Head Contrast: Alpine Immune Sciences (NASDAQ:ALPN) Vs. PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) and PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the
PhaseBio Pharmaceuticals Shares Are Trading Lower After the Company Reported It Received Notice From Nasdaq Stating It Has Determined That the Company's Securities Will Be Delisted From Nasdaq.
PhaseBio Pharmaceuticals shares are trading lower after the company reported it received notice from Nasdaq stating it has determined that the company's securities will be delisted from Nasdaq.
Company Overview
More
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.
CEO： Mr. Jonathan P. Mow
Market： Pink Market
Listing Date： 10/18/2018
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet